Last reviewed · How we verify

Boryung Pharmaceutical Co., Ltd — Portfolio Competitive Intelligence Brief

Boryung Pharmaceutical Co., Ltd pipeline: 5 marketed, 0 filed, 25 Phase 3, 17 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

5 marketed 0 filed 25 Phase 3 17 Phase 2 57 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Dapagliflozin/Pioglitazone Dapagliflozin/Pioglitazone marketed SGLT2 inhibitor / Thiazolidinedione combination SGLT2 / PPAR-γ Diabetes
Aspirin enteric coated pellests 100mg Aspirin enteric coated pellests 100mg marketed
Treatment R Treatment R marketed Calcium channel blocker L-type calcium channels Cardiovascular
Treatment T Treatment T marketed Calcium channel blocker L-type calcium channels Cardiovascular
Dapagliflozin/Sitagliptin Dapagliflozin/Sitagliptin marketed SGLT2 inhibitor / DPP-4 inhibitor combination SGLT2 (sodium-glucose cotransporter 2) and DPP-4 (dipeptidyl peptidase-4) Diabetes
BR1018A BR1018A phase 3 Oncology
BR1019C BR1019C phase 3
BR1018B-1 BR1018B-1 phase 3 ACE2 inhibitor ACE2 Cardiovascular
Perindopril or Perindopril/Indapamide Perindopril or Perindopril/Indapamide phase 3 ACE inhibitor Angiotensin-converting enzyme (ACE) Cardiovascular
DTaP vaccine and IPV vaccine DTaP vaccine and IPV vaccine phase 3 vaccine Immunology
BR1019A BR1019A phase 3
BR1019B BR1019B phase 3

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. GlaxoSmithKline · 6 shared drug classes
  2. Merck Sharp & Dohme LLC · 6 shared drug classes
  3. Novartis · 6 shared drug classes
  4. Sanofi · 6 shared drug classes
  5. Ain Shams University · 4 shared drug classes
  6. Pfizer · 4 shared drug classes
  7. Daewon Pharmaceutical Co., Ltd. · 3 shared drug classes
  8. China National Biotec Group Company Limited · 3 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Boryung Pharmaceutical Co., Ltd:

Cite this brief

Drug Landscape (2026). Boryung Pharmaceutical Co., Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/boryung-pharmaceutical-co-ltd. Accessed 2026-05-16.

Related